

ARTRYA™

Coronary Artery Disease. We see you.

ASX ANNOUNCEMENT MARKET RELEASE

20 June 2025

Issue of Shares on Exercise of Incentive Securities

Artrya Limited (ASX:AYA), ('Artrya' or the 'Company'), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real-time, point-of-care assessment and management of coronary artery disease, advises that a total of 437,856 ordinary shares were issued today on the exercise and conversion of the following vested employee incentive securities:

- 412,856 restricted stock units
- 25,000 performance rights

An Appendix 2A seeking quotation of the shares, will be lodged following this announcement.

This announcement was approved by the Board.

For more information:

Corporate Enquiries

Mathew Regan
Chief Executive Officer
Tel: +61 8 6478 7816
Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger
Hawkesbury Partners
Tel: +61 499 100 038 or +61 410 577 155
Email: investors@artrya.com

About Artrya

Artrya Limited (ASX: AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit www.artrya.com or follow us on LinkedIn at www.linkedin.com/company/artrya

Artrya Limited
ACN 624 005 741
1257 Hay Street West Perth WA 6005
PO Box 567 West Perth WA 6872
www.artrya.com
T: +61 8 6478 7816